Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study
暂无分享,去创建一个
L. Sandvik | J. Bugge | I. Nordøy | E. Helset | E. von der Lippe | V. Bakke | H. Sporsem | Y. Lao | H. Nyrerød | K. R. Hårvig
[1] J. Pachón,et al. Optimizing the Clinical Use of Vancomycin , 2016, Antimicrobial Agents and Chemotherapy.
[2] E. Barcia,et al. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. , 2016, The Journal of antimicrobial chemotherapy.
[3] S. Zhai,et al. Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis , 2016, PloS one.
[4] J. Al-Tawfiq,et al. Safety and Outcome of Pharmacy-Led Vancomycin Dosing and Monitoring , 2015, Chemotherapy.
[5] L. Leibovici,et al. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[6] M. Papas,et al. A Randomized Trial of Loading Vancomycin in the Emergency Department , 2015, The Annals of pharmacotherapy.
[7] S. Zhai,et al. Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Systematic Review , 2014, PloS one.
[8] R. Schmid,et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. , 2014, Journal of critical care.
[9] J. Rello,et al. Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study , 2014, Critical Care.
[10] G. Joynt,et al. Augmented Renal Clearance in the ICU: Results of a Multicenter Observational Study of Renal Function in Critically Ill Patients With Normal Plasma Creatinine Concentrations* , 2014, Critical care medicine.
[11] A. Dubin,et al. Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment , 2014, Revista Brasileira de terapia intensiva.
[12] V. Briedis,et al. Augmented renal clearance – an evolving risk factor to consider during the treatment with vancomycin , 2013, Journal of clinical pharmacy and therapeutics.
[13] S. Zhai,et al. Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis , 2013, PloS one.
[14] D. Siraj,et al. Impact of Regular Collaboration Between Infectious Diseases and Critical Care Practitioners on Antimicrobial Utilization and Patient Outcome* , 2013, Critical care medicine.
[15] A. Hapfelmeier,et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. , 2013, Journal of critical care.
[16] A. Bombassaro,et al. Antimicrobial use in a critical care unit: a prospective observational study , 2012, The International journal of pharmacy practice.
[17] F. Wilson,et al. Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD) , 2011, Clinical nephrology.
[18] M. Palomar,et al. Management of Antimicrobial Use in the Intensive Care Unit , 2012, Drugs.
[19] R. Kullar,et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] D. Levine,et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.